Introduction
Tumor tissues consist of cancer cells and stromal cells. These non-tumor cells may provide suitable niche for tumor progression, and act as barrier to block anti-tumor agents into tumor tissues (1) . Recent studies have suggested that MSCs were potential sources of tumor related stroma (2) (3) (4) (5) (6) . MSCs mainly reside within the bone marrow. They are characteristically able to differentiate into osteoblasts, chondrocytes, adipocytes and other cells (7) (8) (9) . Moreover, these cells can migrate into tumor and participate in tumor development (2) (3) (4) (5) (10) (11) (12) .
It is increasingly recognized that MSCs can exert immune suppression against host eradication of tumor. T cell anergy can be induced by the lack of costimualtory molecules CD40, B7-1 and B7-2 on MSCs (10, 11) . In addition, MSCs can induce immune tolerance via secretion of some soluble inhibitory factor (13) . On the other hand, owing to their potent tropism to tumor tissues, MSCs could be ideal vehicles for targeted delivery of anti-tumor agents to tumor cells. It has been reported that the approaches could mediate tumor regression to certain extents (14) (15) (16) . However, there were some limitations with these previous studies.
For example, some of research just only mixed with modified MSCs with tumors (15) or used xenograft animal model (16) . Furthermore, there were rare reports investigating how to reverse tumor suppressive microenvironments when MSCs used as vehicle.
LIGHT, an acronym for homologous to lymphotoxin, shows inducible expression, and competes with herpes simplex virus glycoprotein D for HVEM, a receptor expressed by T lymphocytes, is a member of the TNF family. LIGHT has a potent, CD28-independent, costimulatory role in T cell activation (17) . LIGHT can interact with lymphotoxin-ȕ receptor (LTβR) and HVEM expressed on stromal cell and T cell respectively (18) . Constitutive (19, 20) .
Moreover, recent data further confirmed the role of LIGHT in priming potent anti-tumor immunity (17, (21) (22) (23) (24) (25) . For instance, we have showed that forced expression of LIGHT in the tumor could induce a massive infiltration of naïve T cells into tumor tissues. Activation of these T cells subsequently led to the rejection of established, highly progressive tumors at local and distal sites (22) . Therefore, LIGHT is an excellent candidate molecule to target tumors by MSCs.
In this study, we investigated whether a stable expression of LIGHT in MSCs (MSC-L) can target delivering LIGHT into tumor tissues, and thereby reverse tumor immunosuppressive environment via LIGHT priming immunity against tumors. Our data showed that MSCs efficiently delivered LIGHT into tumor tissues. We observed that MSC-L enhanced T cell infiltrating into tumors and reversed the local suppressive environment, thereby efficiently control tumor in LIGHT dependent adaptive immunity. 
Materials and Methods
Mice and cell lines. Female aged 6-8 weeks of BALB/c mice were from Shanghai SLAC animal facility. All animal care and experiments were conducted according to Zhejiang University Animal Care Committee guidelines. The murine breast tumor cell line TUBO and human embryonic kidney derived cell line AD293 were cultured in DMEM with 10% FCS.
Isolation, culture and retroviral transduction of marrow MSCs. A female 6-week-old BALB/c mouse was sacrificed, and whole bone marrow was retrieved by flushing the bones with DMEM. All of the bone marrow cells were then cultured in DMEM with 15% FCS for 3 days. The cultured supernatant was harvested as MSCs conditional medium and the nonadherent hematopoietic cells were discarded (7, 9 ). The adherent cells were then washed three times with PBS, added 10ml of DMEM with 10% FCS. When the cells grew to 60% confluence, the cells were transfected with LIGHT expressing retrovirus vector.
For packaging LIGHT expressing retrovirus, AD293 cells were plated with cell density about 50%. After 3-5 hours, the retrovirus was produced by transfecting AD293 with 250 μl Opti-MEM plus 37.5 μl of a solution made by mixing 15 μl LipofectAMINE (Invitrogen) with 7.5 μl of the packaging plasmid pAmpho and 15 μl of pSEB-LIGHT (22) . 3-5 hours later, the medium was discarded and replaced with 4 ml fresh complete DMEM. The retrovirus supernatants were collected at 36, 60 and 84 hours respectively. The generated virus were kept at 4 , or directly used to infect MSCs.
LIGHT gene-modified MSCs were generated by transduction of MSCs twice per day for 2 consecutive days; for more efficient transduction, before 6 hours of adding the retrovirus supernatant, the medium was replaced with fresh MSCs conditional medium to promote MSCs In vitro determination of MSC-L differentiation potential. To determine in vitro differentiation potential of MSC-L, the medium was replaced with osteogenic and adipogenic medium respectively when MSC-L were about 70% confluence. For osteogenic differentiation, MSC-L was cultured for 4 weeks in osteogenic medium containing 10 nM dexamethasone, 50 μg/ml ascorbic 2-phosphate and 10 mM β-glycerol phosphate. To observe calcium deposition, the cultured cells were fixed with 4% paraformaldehyde, and stained with Alizarin Red S. To induce adipogenic differentiation, MSC-L was cultured in adipogenic medium containing 100 nM dexamethasone and 50 μg/ml indomethacine. After fixed with 4% paraformaldehyde, the cells were stained with Oil Red O solution (7, 27) .
In vitro and in vivo migration assay. In vitro migration assay was performed according to the protocol previously described (6, 28) . (Fig. 1B) . Further, mineral deposition was readily detected when MSC-L were stimulated with osteogenic medium, indicating that MSC-L have osteogenic potential (Fig. 1B) . Meanwhile, the oil droplet was found in adipogenic medium, suggesting that MSC-L may differentiate into adipocytes (Fig.   1B) . These results showed that MSC-L retained the MSC's multi-differentiation potential.
We next determined whether MSC-L exhibited any tropism to tumors. With in vitro transwell experiments, we found that MSC-L possessed the potential of migration into tumors (Fig. 1C) . For in vivo migration assay, we found that MSC-L may specifically migrate into tumor and mainly locate in tumor periphery (Fig. 1D, Fig. 1E and Suppl. Fig. 1B ). In addition, the infiltration pattern of MSC-L in tumor was similar with MSC or MSC-mock (Suppl. Fig. 2 ).
Further, LIGHT could be readily detected in tumor tissues after 2 weeks of MSC-L injection (Suppl. To determine whether apoptosis may contribute to tumor inhibition in our experiments, TUNEL were performed after about 2 and 4 weeks of tumor inoculation respectively. Only marginal apoptosis was observed for different groups (Fig. 3B and Suppl. Fig. 5B ). Therefore, it is unlikely that tumor control in our experiments is mainly due to the enhanced tumor apoptosis.
Recently, reports showed that MSCs could contribute to the tumor vasculature formation (15, 34) . To test whether tumor inhibition was due to the MSC-L reversion of the pro-angiogenic effect of MSC, we detected CD31 expression in tumor tissues after about 2 and 4 weeks of 
11 tumor inoculation. The vessel density of MSC-L treated group is the same as control groups (Fig. 3C and Suppl. Fig. 5C ), suggesting that tumor angiogenic inhibition might not be the main mechanism for MSC-L mediated tumor inhibition.
Immune activation by MSC-L contributes to tumor regression. Our previous data have shown that LIGHT could prime potent anti-tumor immunity (22, 24, 25) 
mice, but its level was still lower than in tumor tissues, which indicated that after migration into tumors, MSC-L may largely enhance local inflammation reaction.
Further, we analyzed whether CD4 and CD8 T cells were essential in maintaining tumor control. Either in prophylactic protocol or therapeutic protocol, we observed that, in the induction stage before tumor challenge, CD4 T cells played an important role in tumor control.
At this stage, deletion of CD4 T cells but not CD8 T cells could completely abort the MSC-L
induced anti-tumor immunity (Fig. 5B and Fig. 5C ). Whereas in the effector stage, CD8 T cells were essential for tumor control, since deletion of CD8 T cells largely promoted tumor growth after short time of the continued inhibition ( Fig. 5D and Fig. 5E ); nevertheless, with CD4 deletion in effector stage, the host could still repress tumor growth ( Fig. 5D and 5E ).
Additionally, for the tumor-free or dormant tumor-bearing mice (surgical removal of occult tumors before tumor re-challenge) treated with MSC-L, when re-challenged with 1×10 6 TUBO, they still resisted against tumor growth (Table 1 and Suppl. Table1), which suggests the presence of immune memory for MSC-L treated mice.
Priming immunity of MSC-L was mainly dependent on LIGHT. LIGHT has potent
capability of priming T cell activation independent of CD28 signaling (17) . Our previous studies have shown that expression of LIGHT in the tumor can greatly enhance host resistance to tumor (22, 24) . MSCs might have many molecules that are regulated after transfection of LIGHT. To investigate whether LIGHT is essential for MSC-L mediated-anti-tumor immunity, we first injected LTβR-Ig intraperitoneally to block LIGHT activity in vivo before MSC-L injection. Interestingly, in contrast to the mice without blockade of LIGHT, via consecutive 3 days injection of LTβR-Ig, the tumor posed with aggressive growth tendency ( Fig. 6A and 6B ). Next, we tested whether injection LTβR-Ig after MSC-L inoculation can still abolish MSC-L protection against tumor. At initial duration, for the mice receiving LTβR-Ig after about 1 week and 3 weeks of MSC-L inoculation respectively, the host could continue to resist tumor growth for about 2-3 weeks, but after that time point, the tumors grew aggressively again (Fig. 6C and   6D ), suggesting blockade of LIGHT activity could completely abolish the anti-tumor effect of MSC-L. We then tested whether the blockade of LIGHT activity could delete MSC-L priming T cells activation. Through ELISPOT assays for Ȗ-IFN secretion of T cells, we observed that blockade of LIGHT nearly completely inhibited the T cells producing Ȗ-IFN (Fig. 6E) . Clearly, these data present strong evidence that LIGHT signal pathway is essential for MSC-L priming anti-tumor immunity. 
Discussion
Tumor micro-environment is immunosuppressive (35, 36) , and tumor stroma is often referred as barrier blocking anti-tumor agents into tumors. Since MSCs can home to tumor, MSCs have been used as vehicle for tumor therapy (14, 16) . However, owing to the immunosuppression of MSCs (3, 10, 11, 13, (37) (38) (39) , the efficacy of the treatments would be largely compromised.
How to circumvent its immunosuppression remains illusive when MSCs used as vehicle. exogenous antigens to activate CD8 T cells (40) . MSCs may also act as APC to prime CD4+ T cell proliferation (41, 42) . More recently, report showed that MSCs expressing ErbB-2/neu elicited full protective anti-tumor immunity in vivo (43) . In line with the above findings, we observed that MSC-L can prime anti-tumor immunity to control tumor. Since tumor targeted LIGHT not only can recruit DC and T cells into tumors, but also has a potent, CD28-independent, costimulatory role in priming T cell activation (17) ; whereas MSCs are usually lack of costimulatory molecules CD40, B7-1 and B7-2, which may induce T cell anergy when interact with T cells (13, 37) . In this regard, it remains interesting to investigate whether MSC-L, after migration into tumor, may directly act as APC via LIGHT as costimulatory molecule to prime immunity against tumor, so as to distinct from the role of LIGHT itself directly priming potent anti-tumor immunity. 
